Across TCGA pan-cancer cohorts, SNORA30 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SNORA30’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where SNORA30 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA30 is over-expressed in tumor, although a few such as BRCA and THCA show the opposite, repressed pattern.

STAD, KIRP, and BRCA are the cancer types where SNORA30 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNORA30 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	II,III,IV	+0.475	<.001	7	view →
KIRP	All	II,III,IV	+0.175	.007	4	view →
BRCA	All	IV	−0.180	.019	2	view →
THCA	Female	All	−0.121	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SNORA30 RNA expression & survival · all SNORA30 data types